Alison Bond, Ph.D. has been appointed to lead Quanticate’s new Pharmacovigilance Services team. The new service offers clinical trial and post-marketing pharmacovigilance for comprehensive surveillance throughout the product lifecycle. These services include adverse event case management and reporting, signal detection and evaluation, literature screening and review, and document preparation and submission.

Prior to joining the company, Dr. Bond served as an independent pharmacovigilance consultant, leading the set-up of pharmacovigilance systems for EU Marketing Authorization Applications for a small biopharmaceutical company. Prior to that, she spent eight years at PAREXEL International holding senior management positions in Medical & Pharmacovigilance.

“Centralizing clinical and safety data with Quanticate creates efficiencies for our customers. This signals another exciting development for Quanticate and our customers who need to implement rigorous programs that meet regulatory requirements and protect patients,” said Quanticate’s chief executive officer, David Underwood. “Alison brings several years of experience and a depth of knowledge in this important area of drug development. Her leadership of our Pharmacovigilance Services will be of great value to our customers.”

News from our sister sites